Dublin, Aug. 25, 2016 -- Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025" report to their offering.
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions.
For each company covered, the report provides:
- Corporate Summary
- Total Company Revenue and Total R&D Spending 2011-2015
- Break-up of Sales by Region, 2015
- Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
- Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
- Leading Pharmaceutical Products, 2015 Sales
- Late Stage Product Pipeline
- Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
- Corporate Development Details
The companies covered in this study include:
- Pfizer
- Novartis
- Roche
- Merck
- Sanofi and 20 more
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:
- Pharmaceutical Research & Development Challenge
- The Drug Approval Process
- Expanded Options in Treating Diseases
- Biotechnology Drug Development
- Orphan Drugs
- Fast Track Drug Status
- Other Accelerated Methods for Drug Approval
- Pharmaceutical Regulatory Exclusivity
- The Role of Contract Research Organizations
In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more.
Data provided include:
- Global Pharmaceutical Projects in Development by Therapeutic Segment
- Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
- Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
- Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
- International Population Trend Age 65+
For more information about this report visit http://www.researchandmarkets.com/research/5tjnq3/top_25
Related Topics: Pharmaceuticals
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Instagram Outage Disrupts Thousands of U.S. Users
Washington Post Publisher Will Lewis Steps Down After Layoffs
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



